Shares of Panacea Biotec Ltd hit a 5% upper circuit on Thursday, 26 December, after the company announced receiving a letter of award from UNICEF for supplying 115 million doses of its bivalent oral polio vaccine (bOPV) in CY2025, valued at $14.95 million (Rs 127 crore).
 
In its regulatory filing, the company said that they were awarded a contract by the United Nations International Children’s Emergency Fund (UNICEF) to supply 115 million doses of bivalent oral polio vaccine (bOPV) in the Africa/Asia region, the company filed. The vaccine will be made accessible to regions in 2025. 

Concerns, including child protection, clean water, sanitation, education, nutrition, and health, are among UNICEF’s top priorities. Its efforts are funded by voluntary donations from people and governments.

Panacea Biotec is an Indian biotechnology and pharmaceutical firm that specializes in the research, development, and manufacturing of vaccines, biologics, and pharmaceutical formulations. The business was established in 1984 and is well known for its innovative medical solutions, particularly in the areas of vaccines and life-saving drugs.

The corporation has developed vaccines against polio, tetanus, and hepatitis and has worked with international organizations such as WHO, UNICEF, and Gavi to provide vaccines throughout the world. It also provides drugs to treat cancer, heart disease, diabetes, and organ transplants. Panacea Biotec places a strong focus on research and cutting-edge technologies in an effort to address essential healthcare demands globally.

At 12:37 pm, the shares of Panacea Biotec were trading 3.82% higher at Rs 449.80 on NSE.

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!